DPP4 and cancer: Given its role in cancer biology and the results of multiple preclinical studies, the first in human phase I clinical trial was conducted using a humanized antibody to CD26 (YS110) in malignant mesothelioma patients (22) and reported prolonged disease stabilization with good drug tolerance.